Literature DB >> 18644974

Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells.

Guilian Niu1, Jon Briggs, Jiehui Deng, Yihong Ma, Heehyoung Lee, Marcin Kortylewski, Maciej Kujawski, Heidi Kay, W Douglas Cress, Richard Jove, Hua Yu.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a potent tumorigenic factor. Its alpha subunit (HIF-1alpha), which is tightly regulated in normal tissues, is elevated in tumors due to hypoxia and overactive growth signaling pathways. Although much is known about HIF-1alpha regulation in cancer cells, crucial molecular targets that affect HIF-1alpha levels modulated by both hypoxia and oncogenic signaling pathways remain to be identified. Additionally, whether and how the tumor microenvironment contributes to HIF-1alpha accumulation is unclear. This study shows a novel mechanism by which HIF-1alpha availability is regulated in both cancer cells and in myeloid cells in the tumor microenvironment. We show a requirement of signal transducer and activator of transcription 3 (Stat3) for HIF-1alpha RNA expression under both hypoxia and growth signaling conditions. Furthermore, tumor-derived myeloid cells express elevated levels of HIF-1alpha mRNA relative to their counterparts from normal tissues in a Stat3-dependent manner. Additionally, Stat3 activity in the nontransformed cells in the tumor milieu affects HIF-1alpha RNA expression of the entire growing tumor. Consistent with a role of Stat3 in regulating HIF-1alpha RNA transcription, elevated Stat3 activity increases HIF-1alpha promoter activity, and Stat3 protein binds to the HIF-1alpha promoter in both transformed cells and in growing tumors. Taken together, these findings show a novel mode by which HIF-1alpha is regulated not only in cancer cells but also in the tumor-associated inflammatory cells, suggesting Stat3 as an important molecular target for inhibiting the oncogenic potential of HIF-1 induced by both hypoxia and overactive growth signaling pathways prevalent in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644974      PMCID: PMC2775817          DOI: 10.1158/1541-7786.MCR-07-2177

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  20 in total

Review 1.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.

Authors:  T Hirano; K Ishihara; M Hibi
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 2.  HIF-1 as a target for drug development.

Authors:  Amato Giaccia; Bronwyn G Siim; Randall S Johnson
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Authors:  Guilian Niu; Tammy Bowman; Mei Huang; Steve Shivers; Douglas Reintgen; Adil Daud; Alfred Chang; Alan Kraker; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

5.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Authors:  D Mukhopadhyay; L Tsiokas; X M Zhou; D Foster; J S Brugge; V P Sukhatme
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

6.  Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia.

Authors:  Rotem Karni; Yuval Dor; Eli Keshet; Oded Meyuhas; Alexander Levitzki
Journal:  J Biol Chem       Date:  2002-08-27       Impact factor: 5.157

7.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis.

Authors:  Tong-Xin Xie; Daoyan Wei; Mingguang Liu; Allen C Gao; Francis Ali-Osman; Raymond Sawaya; Suyun Huang
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

Review 8.  Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.

Authors:  Mark W Dewhirst
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Authors:  Tianhong Wang; Guilian Niu; Marcin Kortylewski; Lyudmila Burdelya; Kenneth Shain; Shumin Zhang; Raka Bhattacharya; Dmitry Gabrilovich; Richard Heller; Domenico Coppola; William Dalton; Richard Jove; Drew Pardoll; Hua Yu
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

View more
  76 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

2.  HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway.

Authors:  L Qiang; T Wu; H-W Zhang; N Lu; R Hu; Y-J Wang; L Zhao; F-H Chen; X-T Wang; Q-D You; Q-L Guo
Journal:  Cell Death Differ       Date:  2011-08-05       Impact factor: 15.828

3.  STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α.

Authors:  Chi Zhang; Xi Yang; Qu Zhang; Qing Guo; Jia He; Qin Qin; Hongcheng Zhu; Jia Liu; Liangliang Zhan; Jing Lu; Zheming Liu; Liping Xu; Jianxin Ma; Shengbin Dai; Hongyan Cheng; Xinchen Sun
Journal:  Tumour Biol       Date:  2014-07-01

Review 4.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

5.  Leptin signaling is required for augmented therapeutic properties of mesenchymal stem cells conferred by hypoxia preconditioning.

Authors:  Xinyang Hu; Rongrong Wu; Zhi Jiang; Lihan Wang; Panpan Chen; Ling Zhang; Lu Yang; Yan Wu; Han Chen; Huiqiang Chen; Yinchuan Xu; Yu Zhou; Xin Huang; Keith A Webster; Hong Yu; Jian'an Wang
Journal:  Stem Cells       Date:  2014-10       Impact factor: 6.277

6.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

7.  Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.

Authors:  S E Wheeler; S Suzuki; S M Thomas; M Sen; R J Leeman-Neill; S I Chiosea; C-T Kuan; D D Bigner; W E Gooding; S Y Lai; J R Grandis
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

Review 8.  Redox control of inflammation in macrophages.

Authors:  Bernhard Brüne; Nathalie Dehne; Nina Grossmann; Michaela Jung; Dmitry Namgaladze; Tobias Schmid; Andreas von Knethen; Andreas Weigert
Journal:  Antioxid Redox Signal       Date:  2013-03-06       Impact factor: 8.401

9.  Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.

Authors:  Rebecca J Leeman-Neill; Sarah E Wheeler; Shivendra V Singh; Sufi M Thomas; Raja R Seethala; Daniel B Neill; Mary C Panahandeh; Eun-Ryeong Hahm; Sonali C Joyce; Malabika Sen; Quan Cai; Maria L Freilino; Changyou Li; Daniel E Johnson; Jennifer R Grandis
Journal:  Carcinogenesis       Date:  2009-09-16       Impact factor: 4.944

10.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.

Authors:  M R Pawlus; L Wang; C-J Hu
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.